Vedanta Biosciences
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection
$60MGrowth
Role not disclosedBP
BNP Paribas Asset Management Alts
Activity from announced rounds
Activity in this selectionstan-boland-a8b1bac1
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $175M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionILiAD Biotechnologies
Developing a next-generation pertussis vaccine candidate BPZE1
$115MSeries B
Role not disclosed